Max Healthcare Sees 16% Revenue Growth in Q1 FY27, Plans Medical Education Venture

Max Healthcare's network gross revenue reached Rs 2,982 crore in Q1 FY27, a 16% increase year-on-year, and 12% quarter-on-quarter. Network Operating EBITDA rose 15% YoY to Rs 704 crore.

Reader Takeaway: Strong revenue growth and strategic expansion plans are positive, but margin pressure and rising AR are near-term concerns.

What just happened

Max Healthcare reported a 16% year-on-year increase in network gross revenue for the first quarter of FY27, reaching Rs 2,982 crore. Operating EBITDA grew 15% to Rs 704 crore. The company's board also granted in-principle approval to enter the medical education sector, aiming for over 25% ROCEs. Additionally, a Rs 425 crore CAPEX was approved for a 202-bed brownfield tower expansion at its Vaishali facility.

Why this matters

The revenue growth indicates continued demand for Max Healthcare's services. The strategic pivot into medical education could create a new, long-term growth avenue and a pipeline for clinical talent. The expansion at Vaishali signals continued investment in capacity. However, a slight dip in EBITDA margins to 24.8% from 24.9% YoY and an increase in Days Sales Outstanding (DSO) to 95 days warrant attention.

The backstory

Max Healthcare has been focused on organic expansion and strategic acquisitions. Recent moves include acquiring Kalinga Hospital and Yerawada Properties in Pune, and commissioning parts of the Max Smart facility. The company has been increasing its operational bed capacity while maintaining high occupancy rates above 75%.

What changes now

The approval for medical education is a significant strategic shift. The Vaishali expansion will add capacity, and the Pune greenfield SPV acquisition is a step towards new facility development. The company expects the commissioning of the remaining beds at Max Smart in the current quarter.

Risks to watch

Near-term margin pressure due to new capacity commissioning and hospital acquisitions is a concern. An increase in AR, particularly from CGHS and PSUs, has led to higher DSO, impacting cash flow. Management is also consciously managing institutional patient volumes, which are considered less profitable.

Peer comparison

While specific peer results are not detailed in the filing, Max Healthcare's revenue growth of 16% should be viewed against the backdrop of the broader Indian healthcare sector's recovery and expansion trends. Competitors like Apollo Hospitals and Fortis Healthcare are also investing in capacity and new services.

Context metrics (time-bound)

• Network Gross Revenue: Rs 2,982 crore (Q1 FY27)
• Network Operating EBITDA: Rs 704 crore (Q1 FY27)
• EBITDA Margin: 24.8% (Q1 FY27)
• ARPOB: Rs 81,900 (Q1 FY27)
• Max@Home revenue: Rs 78 crore (Q1 FY27)
• Max Lab revenue: Rs 58 crore (Q1 FY27)
• Net Debt: Rs 2,384 crore (Q1 FY27)
• Days Sales Outstanding (DSO): 95 days (Q1 FY27)

What to track next

Investors will be looking for updates on the execution strategy for the medical education business, the ramp-up of new capacities, and margin recovery. Monitoring DSO and collection cycles will also be crucial.